Doctors hail Moderna-Merck melanoma vaccine data despite Wall Street selloff

· Health · United States

Leaked data from Moderna and Merck's highly anticipated melanoma vaccine trial drew cheers from oncologists while Wall Street sold off the stocks, a rare disconnect. Six melanoma specialists said the results represent a clinically meaningful outcome for melanoma patients who underwent surgery. Normally pivotal drug studies are binary, with doctors, patients and investors all learning the outcome together. The gap highlights how difficult it can be for markets to price novel cancer treatments whose benefit may not fit conventional trial endpoints.

Why it matters：If confirmed, a clinically meaningful cancer vaccine would be a major advance in oncology and reshape expectations for mRNA-based treatments.

Key points

  • Six melanoma specialists called the results clinically meaningful
  • Wall Street sold off Moderna and Merck shares
  • The data leaked ahead of formal release

Sources (original reporting)

More stories from this day